Biological Information

Background Information:

The abl oncogene was initially identified as the viral transforming gene (v-abl) of Abelson murine leukemia virus (A-MuLV), from a chemically thymectomized mouse inoculated with Moloney murine leukemia virus (M-MuLV). The v-abl genome consists of M-MuLV gag sequences fused to mouse c-abl, resulting in the production of phosphoproteins, p160 and p120 gag/c-abl with protein-tyrosine kinase activity, as the major translational products. The abl oncogene is implicated in serval human leukemias including chronic myelocytic (CML), adult acute lymphoblastic (ALL) and pediatric ALL. In these leukemias the c-abl proto-oncogene undergoes a chromosomal translocation producing the Philadelphia (;) chromosome resulting in the fusion of c-abl sequences to the bcr gene of chromosome 22, and the molecular consequences of this translocation is the generation of a chimeric bcr/c-abl mRNA encoding activated abl protein-tyrosine kinase.

Target Class:

Kinase

Family:

TK

Sub Family:

Protein Tyrosine

Protein Name:

Abl

Protein Aliases:

Abelson murine leukemia viral oncogene homolog 1|Abelson tyrosine-protein kinase 1|Proto-oncogene c-Abl|p150

Accession Number:

J02995.1

UniProt Number:

P00520

Gene Name:

Abl1

Gene ID:

11350

Gene Aliases:

JTK7|c-ABL|p150

Target Species:

Mouse

Usage

Product Type:

Enzymes

Application:

Drug Discovery & Development

Storage Conditions:

1 year at -70°C

Usage disclaimer:

These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.

Assay Information

Assay Type:

Enzymatic

Clinical Relevance

Therapeutic Area:

Oncology/Immuno-Oncology